DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US10590418B2
(en)
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
JP2005508306A
(ja)
|
2001-07-23 |
2005-03-31 |
ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ |
哺乳類における遺伝子発現のRNAiによる阻害に関する方法および組成物
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
DE10163098B4
(de)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US8258288B2
(en)
*
|
2002-02-20 |
2012-09-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
|
ATE427352T1
(de)
|
2002-07-26 |
2009-04-15 |
Novartis Vaccines & Diagnostic |
Modifizierte kleine irns molekule und methoden zu deren anwendung
|
AU2003282877B9
(en)
|
2002-09-25 |
2011-05-12 |
University Of Massachusetts |
In Vivo gene silencing by chemically modified and stable siRNA
|
US20050043266A1
(en)
*
|
2003-07-25 |
2005-02-24 |
Sumedha Jayasena |
Short interfering RNA as an antiviral agent for hepatitis C
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
JP2007505606A
(ja)
*
|
2003-09-16 |
2007-03-15 |
サーナ・セラピューティクス・インコーポレイテッド |
低分子干渉核酸(siNA)を使用したC型肝炎ウィルス(HCV)発現のRNA干渉媒介性抑制
|
WO2005087926A2
(en)
|
2004-03-05 |
2005-09-22 |
Benitec, Inc. |
Multiple promoter expression cassettes for simultaneous delivery of rnai agents
|
AU2011250867A1
(en)
*
|
2004-05-04 |
2011-12-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for reducing viral genome amounts in a target cell
|
EP1747023B2
(en)
|
2004-05-04 |
2016-03-09 |
The Board of Trustees of The Leland Stanford Junior University |
Methods and compositions for reducing hcv viral genome amounts in a target cell
|
US20090170794A1
(en)
|
2004-09-10 |
2009-07-02 |
Somagenics Inc. |
Small interfering rnas that efficiently inhibit viral expression and methods of use thereof
|
CA2824308A1
(en)
*
|
2004-09-24 |
2006-04-06 |
Alnylam Pharmaceuticals, Inc. |
Targeting opposite strand replication intermediates of single-stranded viruses by rnai
|
JPWO2006038608A1
(ja)
*
|
2004-10-05 |
2008-05-15 |
日本新薬株式会社 |
オリゴ二本鎖rna及び医薬組成物
|
EP1844145A2
(en)
*
|
2005-02-03 |
2007-10-17 |
Benitec, Inc. |
Rnai expression constructs
|
NZ594810A
(en)
*
|
2005-03-15 |
2012-12-21 |
Verenium Corp |
Cellulases, nucleic acids encoding them and methods for making and using them
|
US7919583B2
(en)
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
CN101305095B
(zh)
*
|
2005-09-12 |
2012-09-26 |
索马根尼科斯公司 |
利用小干扰rna抑制病毒基因表达
|
CN102851291B
(zh)
|
2006-04-03 |
2016-03-09 |
斯特拉有限责任公司 |
包含抗微小rna反义寡核苷酸的药物组合物
|
KR101407707B1
(ko)
|
2006-04-03 |
2014-06-19 |
산타리스 팔마 에이/에스 |
Anti-mirna 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
|
WO2008009477A2
(en)
|
2006-07-21 |
2008-01-24 |
Silence Therapeutics Ag |
Means for inhibiting the expression of protein kinase 3
|
EP1886685A1
(en)
*
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2144604B1
(en)
|
2007-02-28 |
2011-09-21 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
SI2308514T1
(sl)
|
2007-03-23 |
2013-09-30 |
To-Bbb Holding B.V. |
Konjugati za prenos zdravila preko krvno-moĹľganske pregrade
|
JP5296328B2
(ja)
*
|
2007-05-09 |
2013-09-25 |
独立行政法人理化学研究所 |
1本鎖環状rnaおよびその製造方法
|
CN101688206B
(zh)
|
2007-07-05 |
2013-05-15 |
诺瓦提斯公司 |
用于治疗病毒感染的dsRNA
|
US8415323B2
(en)
|
2007-08-27 |
2013-04-09 |
The Regents Of The University Of California |
MicroRNAs for inhibiting viral replication
|
CN101821391B
(zh)
|
2007-10-04 |
2016-04-27 |
桑塔里斯制药公司 |
微小聚体
|
US8404659B2
(en)
|
2008-03-07 |
2013-03-26 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of MicroRNA related diseases
|
RU2519947C2
(ru)
|
2008-07-02 |
2014-06-20 |
Айденикс Фармасьютикалз, Инк. |
Соединения и фармацевтические композиции для лечения вирусных инфекций
|
WO2010008562A2
(en)
|
2008-07-16 |
2010-01-21 |
Recombinetics |
Methods and materials for producing transgenic animals
|
WO2010012667A1
(en)
|
2008-08-01 |
2010-02-04 |
Santaris Pharma A/S |
Micro-rna mediated modulation of colony stimulating factors
|
WO2010045384A2
(en)
|
2008-10-15 |
2010-04-22 |
Somagenics Inc. |
Short hairpin rnas for inhibition of gene expression
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
EP2421970B1
(en)
|
2009-04-24 |
2016-09-07 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
|
US8871730B2
(en)
|
2009-07-13 |
2014-10-28 |
Somagenics Inc. |
Chemical modification of short small hairpin RNAs for inhibition of gene expression
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
MX2012006877A
(es)
|
2009-12-18 |
2012-08-31 |
Idenix Pharmaceuticals Inc |
Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
|
CN102917585A
(zh)
|
2010-04-01 |
2013-02-06 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
US9243246B2
(en)
|
2010-08-24 |
2016-01-26 |
Sirna Therapeutics, Inc. |
Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
CA2843324A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2755983B1
(en)
|
2011-09-12 |
2017-03-15 |
Idenix Pharmaceuticals LLC. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
AU2012308900A1
(en)
|
2011-09-12 |
2013-05-09 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
CA2856722C
(en)
|
2011-11-30 |
2022-11-22 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
WO2013133927A1
(en)
|
2012-02-13 |
2013-09-12 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
MX355708B
(es)
|
2012-05-22 |
2018-04-27 |
Idenix Pharmaceuticals Llc |
Compuestos de d-aminoacidos para enfermedades del higado.
|
US9109001B2
(en)
|
2012-05-22 |
2015-08-18 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphoramidate prodrugs for HCV infection
|
CA2887578A1
(en)
|
2012-10-08 |
2014-04-17 |
Idenix Pharamaceuticals, Inc. |
2'-chloro nucleoside analogs for hcv infection
|
EP2909223B1
(en)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinucleotide compounds for hcv infection
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
EP2938624A1
(en)
|
2012-11-14 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
US20160271162A1
(en)
|
2013-11-01 |
2016-09-22 |
Idenix Pharmacueticals, Llc |
D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
|
WO2015081297A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
US10370730B2
(en)
|
2013-12-11 |
2019-08-06 |
Saitama Medical University |
Detection method for mutation in 93rd amino acid of hepatitis C virus NS5A protein, and detection kit for mutation in 93rd amino acid of hepatitis C virus NS54 protein
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
EP3113763A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
CA2998370A1
(en)
|
2015-09-17 |
2017-03-23 |
Moderna Therapeutics, Inc. |
Polynucleotides containing a stabilizing tail region
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
WO2017197036A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
GB201819726D0
(en)
*
|
2018-12-03 |
2019-01-16 |
Diagnostics For The Real World Ltd |
HCV detection
|
WO2022223515A2
(en)
|
2021-04-19 |
2022-10-27 |
Novo Nordisk A/S |
Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
|